Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors

Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracen...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Sebastian Regnery [verfasserIn] Tanja Eichkorn [verfasserIn] Fabian Weykamp [verfasserIn] Thomas Held [verfasserIn] Lisa-Antonia Dinges [verfasserIn] Fabian Schunn [verfasserIn] Hauke Winter [verfasserIn] Michael Thomas [verfasserIn] Jürgen Debus [verfasserIn] Rami A. El Shafie [verfasserIn] Sebastian Adeberg [verfasserIn] Juliane Hörner-Rieber [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function

Übergeordnetes Werk:	In: Cancers - MDPI AG, 2010, 12(2020), 10, p 2862
Übergeordnetes Werk:	volume:12 ; year:2020 ; number:10, p 2862

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cancers12102862

Katalog-ID:	DOAJ046943285

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ046943285
003	DE-627
005	20240412212418.0
007	cr uuu---uuuuu
008	230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cancers12102862 \|2 doi
035			\|a (DE-627)DOAJ046943285
035			\|a (DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Sebastian Regnery \|e verfasserin \|4 aut
245	1	0	\|a Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up.
650		4	\|a SBRT
650		4	\|a non-small cell lung cancer
650		4	\|a oligometastases
650		4	\|a central
650		4	\|a ultracentral
650		4	\|a pulmonary function
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Tanja Eichkorn \|e verfasserin \|4 aut
700	0		\|a Fabian Weykamp \|e verfasserin \|4 aut
700	0		\|a Thomas Held \|e verfasserin \|4 aut
700	0		\|a Lisa-Antonia Dinges \|e verfasserin \|4 aut
700	0		\|a Fabian Schunn \|e verfasserin \|4 aut
700	0		\|a Hauke Winter \|e verfasserin \|4 aut
700	0		\|a Michael Thomas \|e verfasserin \|4 aut
700	0		\|a Jürgen Debus \|e verfasserin \|4 aut
700	0		\|a Rami A. El Shafie \|e verfasserin \|4 aut
700	0		\|a Sebastian Adeberg \|e verfasserin \|4 aut
700	0		\|a Juliane Hörner-Rieber \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cancers \|d MDPI AG, 2010 \|g 12(2020), 10, p 2862 \|w (DE-627)614095670 \|w (DE-600)2527080-1 \|x 20726694 \|7 nnns
773	1	8	\|g volume:12 \|g year:2020 \|g number:10, p 2862
856	4	0	\|u https://doi.org/10.3390/cancers12102862 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6694/12/10/2862 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 12 \|j 2020 \|e 10, p 2862

Indexfelder

author_variant	s r sr t e te f w fw t h th l a d lad f s fs h w hw m t mt j d jd r a e s raes s a sa j h r jhr
matchkey_str	article:20726694:2020----::rgesooploayucinncreainihuvvlolwnseetcibdrdohrp
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.3390/cancers12102862 doi (DE-627)DOAJ046943285 (DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01 DE-627 ger DE-627 rakwb eng RC254-282 Sebastian Regnery verfasserin aut Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up. SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tanja Eichkorn verfasserin aut Fabian Weykamp verfasserin aut Thomas Held verfasserin aut Lisa-Antonia Dinges verfasserin aut Fabian Schunn verfasserin aut Hauke Winter verfasserin aut Michael Thomas verfasserin aut Jürgen Debus verfasserin aut Rami A. El Shafie verfasserin aut Sebastian Adeberg verfasserin aut Juliane Hörner-Rieber verfasserin aut In Cancers MDPI AG, 2010 12(2020), 10, p 2862 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:10, p 2862 https://doi.org/10.3390/cancers12102862 kostenfrei https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01 kostenfrei https://www.mdpi.com/2072-6694/12/10/2862 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 10, p 2862
spelling	10.3390/cancers12102862 doi (DE-627)DOAJ046943285 (DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01 DE-627 ger DE-627 rakwb eng RC254-282 Sebastian Regnery verfasserin aut Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up. SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tanja Eichkorn verfasserin aut Fabian Weykamp verfasserin aut Thomas Held verfasserin aut Lisa-Antonia Dinges verfasserin aut Fabian Schunn verfasserin aut Hauke Winter verfasserin aut Michael Thomas verfasserin aut Jürgen Debus verfasserin aut Rami A. El Shafie verfasserin aut Sebastian Adeberg verfasserin aut Juliane Hörner-Rieber verfasserin aut In Cancers MDPI AG, 2010 12(2020), 10, p 2862 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:10, p 2862 https://doi.org/10.3390/cancers12102862 kostenfrei https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01 kostenfrei https://www.mdpi.com/2072-6694/12/10/2862 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 10, p 2862
allfields_unstemmed	10.3390/cancers12102862 doi (DE-627)DOAJ046943285 (DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01 DE-627 ger DE-627 rakwb eng RC254-282 Sebastian Regnery verfasserin aut Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up. SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tanja Eichkorn verfasserin aut Fabian Weykamp verfasserin aut Thomas Held verfasserin aut Lisa-Antonia Dinges verfasserin aut Fabian Schunn verfasserin aut Hauke Winter verfasserin aut Michael Thomas verfasserin aut Jürgen Debus verfasserin aut Rami A. El Shafie verfasserin aut Sebastian Adeberg verfasserin aut Juliane Hörner-Rieber verfasserin aut In Cancers MDPI AG, 2010 12(2020), 10, p 2862 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:10, p 2862 https://doi.org/10.3390/cancers12102862 kostenfrei https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01 kostenfrei https://www.mdpi.com/2072-6694/12/10/2862 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 10, p 2862
allfieldsGer	10.3390/cancers12102862 doi (DE-627)DOAJ046943285 (DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01 DE-627 ger DE-627 rakwb eng RC254-282 Sebastian Regnery verfasserin aut Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up. SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tanja Eichkorn verfasserin aut Fabian Weykamp verfasserin aut Thomas Held verfasserin aut Lisa-Antonia Dinges verfasserin aut Fabian Schunn verfasserin aut Hauke Winter verfasserin aut Michael Thomas verfasserin aut Jürgen Debus verfasserin aut Rami A. El Shafie verfasserin aut Sebastian Adeberg verfasserin aut Juliane Hörner-Rieber verfasserin aut In Cancers MDPI AG, 2010 12(2020), 10, p 2862 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:10, p 2862 https://doi.org/10.3390/cancers12102862 kostenfrei https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01 kostenfrei https://www.mdpi.com/2072-6694/12/10/2862 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 10, p 2862
allfieldsSound	10.3390/cancers12102862 doi (DE-627)DOAJ046943285 (DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01 DE-627 ger DE-627 rakwb eng RC254-282 Sebastian Regnery verfasserin aut Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up. SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function Neoplasms. Tumors. Oncology. Including cancer and carcinogens Tanja Eichkorn verfasserin aut Fabian Weykamp verfasserin aut Thomas Held verfasserin aut Lisa-Antonia Dinges verfasserin aut Fabian Schunn verfasserin aut Hauke Winter verfasserin aut Michael Thomas verfasserin aut Jürgen Debus verfasserin aut Rami A. El Shafie verfasserin aut Sebastian Adeberg verfasserin aut Juliane Hörner-Rieber verfasserin aut In Cancers MDPI AG, 2010 12(2020), 10, p 2862 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:12 year:2020 number:10, p 2862 https://doi.org/10.3390/cancers12102862 kostenfrei https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01 kostenfrei https://www.mdpi.com/2072-6694/12/10/2862 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2020 10, p 2862
language	English
source	In Cancers 12(2020), 10, p 2862 volume:12 year:2020 number:10, p 2862
sourceStr	In Cancers 12(2020), 10, p 2862 volume:12 year:2020 number:10, p 2862
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Cancers
authorswithroles_txt_mv	Sebastian Regnery @@aut@@ Tanja Eichkorn @@aut@@ Fabian Weykamp @@aut@@ Thomas Held @@aut@@ Lisa-Antonia Dinges @@aut@@ Fabian Schunn @@aut@@ Hauke Winter @@aut@@ Michael Thomas @@aut@@ Jürgen Debus @@aut@@ Rami A. El Shafie @@aut@@ Sebastian Adeberg @@aut@@ Juliane Hörner-Rieber @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	614095670
id	DOAJ046943285
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ046943285</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412212418.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers12102862</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ046943285</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sebastian Regnery</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SBRT</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-small cell lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oligometastases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">central</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ultracentral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pulmonary function</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tanja Eichkorn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabian Weykamp</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Held</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lisa-Antonia Dinges</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabian Schunn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hauke Winter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jürgen Debus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rami A. El Shafie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sebastian Adeberg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Juliane Hörner-Rieber</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">12(2020), 10, p 2862</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:10, p 2862</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers12102862</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/12/10/2862</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2020</subfield><subfield code="e">10, p 2862</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Sebastian Regnery
spellingShingle	Sebastian Regnery misc RC254-282 misc SBRT misc non-small cell lung cancer misc oligometastases misc central misc ultracentral misc pulmonary function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
authorStr	Sebastian Regnery
ppnlink_with_tag_str_mv	@@773@@(DE-627)614095670
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	20726694
topic_title	RC254-282 Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors SBRT non-small cell lung cancer oligometastases central ultracentral pulmonary function
topic	misc RC254-282 misc SBRT misc non-small cell lung cancer misc oligometastases misc central misc ultracentral misc pulmonary function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc SBRT misc non-small cell lung cancer misc oligometastases misc central misc ultracentral misc pulmonary function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc SBRT misc non-small cell lung cancer misc oligometastases misc central misc ultracentral misc pulmonary function misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cancers
hierarchy_parent_id	614095670
hierarchy_top_title	Cancers
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614095670 (DE-600)2527080-1
title	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
ctrlnum	(DE-627)DOAJ046943285 (DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01
title_full	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
author_sort	Sebastian Regnery
journal	Cancers
journalStr	Cancers
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Sebastian Regnery Tanja Eichkorn Fabian Weykamp Thomas Held Lisa-Antonia Dinges Fabian Schunn Hauke Winter Michael Thomas Jürgen Debus Rami A. El Shafie Sebastian Adeberg Juliane Hörner-Rieber
container_volume	12
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Sebastian Regnery
doi_str_mv	10.3390/cancers12102862
author2-role	verfasserin
title_sort	progression of pulmonary function and correlation with survival following stereotactic body radiotherapy of central and ultracentral lung tumors
callnumber	RC254-282
title_auth	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
abstract	Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up.
abstractGer	Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up.
abstract_unstemmed	Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	10, p 2862
title_short	Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
url	https://doi.org/10.3390/cancers12102862 https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01 https://www.mdpi.com/2072-6694/12/10/2862 https://doaj.org/toc/2072-6694
remote_bool	true
author2	Tanja Eichkorn Fabian Weykamp Thomas Held Lisa-Antonia Dinges Fabian Schunn Hauke Winter Michael Thomas Jürgen Debus Rami A. El Shafie Sebastian Adeberg Juliane Hörner-Rieber
author2Str	Tanja Eichkorn Fabian Weykamp Thomas Held Lisa-Antonia Dinges Fabian Schunn Hauke Winter Michael Thomas Jürgen Debus Rami A. El Shafie Sebastian Adeberg Juliane Hörner-Rieber
ppnlink	614095670
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cancers12102862
callnumber-a	RC254-282
up_date	2024-07-03T23:20:34.766Z
_version_	1803601926970933249
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ046943285</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412212418.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers12102862</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ046943285</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ8491a24031ec4196841f5ee3a6683f01</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sebastian Regnery</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Stereotactic body radiotherapy (SBRT) to central and ultracentral lung tumors carries a risk of excessive toxicity. This study analyzed changes in pulmonary function tests (PFT) and their correlation with overall survival (OS) in 107 patients following central (<i<n</i< = 62) or ultracentral (<i<n</i< = 45) lung SBRT. Ultracentral location was defined as planning target volume overlap with the proximal bronchial tree (PBT). Vital capacity (VC) (−0.3 l, absolute −9.4% of predicted, both <i<p</i< < 0.001) and forced expiratory volume in the first second (FEV<sub<1s</sub<) (−0.2 l, absolute −7.7% of predicted, both <i<p</i< < 0.001) significantly decreased following SBRT. Higher maximum dose to the PBT significantly correlated with a steeper decline in VC (<i<p</i< = 0.005) and FEV<sub<1s</sub< (<i<p</i< = 0.03) over time. Pronounced decline in FEV<sub<1s</sub< between 6 and 12 months (HR = 0.90, <i<p</i< = 0.006) and pronounced decline in VC between baseline and 12 months (HR = 0.95, <i<p</i< = 0.004) independently correlated with worse OS. Consequently, PFT presented a statistically significant albeit clinically mild decrease in lung volumes following central and ultracentral SBRT that correlated moderately with maximum dose to the PBT. Stronger decline in pulmonary function was associated with constrained survival, advocating consequent performance of PFT during follow-up.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SBRT</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-small cell lung cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oligometastases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">central</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ultracentral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pulmonary function</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tanja Eichkorn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabian Weykamp</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Thomas Held</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lisa-Antonia Dinges</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fabian Schunn</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hauke Winter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jürgen Debus</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rami A. El Shafie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sebastian Adeberg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Juliane Hörner-Rieber</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">12(2020), 10, p 2862</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:10, p 2862</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers12102862</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/8491a24031ec4196841f5ee3a6683f01</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/12/10/2862</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2020</subfield><subfield code="e">10, p 2862</subfield></datafield></record></collection>
score	7.4020205

Nicht das Richtige dabei?

Schreiben Sie uns!

Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?